

Q3 cont

Deposit of Microorganisms for the Purpose of Patent Procedure, deposit of a hybridoma, KKO, will be made with the American Type Culture Collection (ATCC) of Manassas, Virginia, USA, where the deposits are given ATCC Accession Numbers _____. The assignee, Science & Technology Corporation @ UNM, represents that the ATCC is a depository afforded permanence of the deposit and ready accessibility thereto by the public if a patent is granted. All restrictions on the availability to the public of the material so deposited will be irrevocably removed upon granting of a patent. The material will be readily available during the pendency of the patent application to one determined by the Commissioner to be entitled thereto under 37 C.F.R. § 1.14 and 35 U.S.C. § 122. The deposited material will be maintained with all the care necessary to keep it viable and uncontaminated for a period of at least five years after the most recent request for the furnishing of a sample of the deposited material, and in any case, for a period of at least thirty (30) years after the date of the deposit or for the enforceable life of the patent, whichever period is longer. Applicant's assignee acknowledges its duty to replace the deposit should the depository be unable to furnish a sample when requested due to the condition of the deposit. --

In the Claims:

Please amend claims 1, 2, 3, 4, 5, 12, 13, and 14, without prejudice and add new claims 40 and 41 as follows:

A4

1. (Amended) A composition comprising a monoclonal antibody which is capable of binding specifically with a platelet factor 4 (PF4)/heparin complex, wherein said antibody preferentially binds with said PF4/heparin complex relative to said binding with either PF4 or heparin alone.

2. (Amended) The composition of claim 1, wherein said monoclonal antibody is capable of binding specifically with a PF4/glycosaminoglycan complex, wherein said glycosaminoglycan is not heparin.

3. (Amended) The composition of claim 1, wherein said monoclonal antibody is capable of activating platelets with PF4 and heparin present.

4. (Amended) The composition of claim 1, wherein said antibody comprises a heavy chain polypeptide having an amino acid sequence which shares at least about 80% sequence identity with SEQ ID NO:1 and a light chain polypeptide having an amino acid sequence which shares at least about 80% sequence identity with SEQ ID NO:2.

Q4
5. (Amended) The composition of claim 1, wherein is said antibody is a murine monoclonal antibody which comprises a heavy chain polypeptide of SEQ ID NO:1 and a light chain polypeptide of SEQ ID NO:2.

12. (Amended) A method of making a humanized monoclonal antibody which is capable of binding specifically with a platelet factor 4 (PF4)/heparin complex, wherein said antibody preferentially binds with said PF4/heparin complex relative to said binding of said antibody with either PF4 or heparin alone, said method comprising

a) obtaining a monoclonal antibody which is capable of binding specifically with a PF4/heparin complex, wherein said antibody preferentially binds with said PF4/heparin complex relative to said binding of said antibody with either PF4 or heparin alone;

Q5
b) humanizing said antibody in a), whereby a humanized monoclonal antibody is made.

13. (Amended) The method of claim 12, wherein said monoclonal antibody in a) comprises a heavy chain polypeptide having an amino acid sequence which shares at least about 80% sequence identity with SEQ ID NO:1 and a light chain polypeptide having an amino acid sequence which shares at least about 80% sequence identity with SEQ ID NO:2.

14. (Amended) The method of claim 12, wherein said monoclonal antibody in a) is a murine monoclonal antibody which comprises a heavy chain polypeptide of SEQ ID NO:1 and a light chain polypeptide of SEQ ID NO:2.
